FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2080335269> ?p ?o ?g. }

• W2080335269 endingPage "209" @default.
• W2080335269 startingPage "195" @default.
• W2080335269 abstract "Abstract: Although the three (perhaps four) phases of clinical drug development are well known, it is relatively unappreciated that there are similar phases in pre-clinical development. These consist of ‘Phase I’ the initial, normally Research Discovery driven pharmacology; ‘Phase II’ non-good laboratory practice (GLP) dose range finding, followed by pivotal ‘Phase III’ GLP toxicology. Together with an array of in vitro experiments comparing species, these stages should enable an integrated safety assessment prior to entry into man, documenting to investigators and authorities evidence that the new pharmaceutic is unlikely to cause harm. Following the lessons learned from TeGenero TGN1412 and subsequent updates to regulatory guidelines, there are aspects peculiar to biotherapeutics, especially those that target key body systems, where calculations could be made for doses for human studies using pharmacokinetic and pharmacodynamic models. Two of these are exemplified in this paper. In the first, target-mediated drug disposition, where the binding of the drug to a cellular target quantitatively affects the pharmacokinetics, enables occupancy to be estimated without recourse to independent assays. In the second, assaying captured soluble target, as drug-target complexes, allows estimation of the concentration of the free ligand ensuring that in initial clinical studies, soluble targets are not overly suppressed. To support this methodology, it has been demonstrated using omalizumab, free and total IgE data that such analyses do predict the suppression of the free unbound ligand with reasonable accuracy. Overall, the objective of the process is to deliver a justification, through consideration of drug-target binding, of a safe starting and therapeutically relevant escalation doses for human studies." @default.
• W2080335269 created "2016-06-24" @default.
• W2080335269 creator A5005464911 @default.
• W2080335269 creator A5008858755 @default.
• W2080335269 creator A5018442681 @default.
• W2080335269 creator A5028028709 @default.
• W2080335269 creator A5077859754 @default.
• W2080335269 date "2010-03-01" @default.
• W2080335269 modified "2023-09-27" @default.
• W2080335269 title "On Setting the First Dose in Man: Quantitating Biotherapeutic Drug-Target Binding through Pharmacokinetic and Pharmacodynamic Models" @default.
• W2080335269 cites W1525774039 @default.
• W2080335269 cites W1987432442 @default.
• W2080335269 cites W1998532042 @default.
• W2080335269 cites W2000902397 @default.
• W2080335269 cites W2010216472 @default.
• W2080335269 cites W2011018995 @default.
• W2080335269 cites W2029587541 @default.
• W2080335269 cites W2034176270 @default.
• W2080335269 cites W2039103439 @default.
• W2080335269 cites W2039164436 @default.
• W2080335269 cites W2047805567 @default.
• W2080335269 cites W2059889603 @default.
• W2080335269 cites W2062826169 @default.
• W2080335269 cites W2072162251 @default.
• W2080335269 cites W2076171495 @default.
• W2080335269 cites W2080843536 @default.
• W2080335269 cites W2081729073 @default.
• W2080335269 cites W2110348886 @default.
• W2080335269 cites W2112375529 @default.
• W2080335269 cites W2155284019 @default.
• W2080335269 cites W2164367822 @default.
• W2080335269 cites W2164977460 @default.
• W2080335269 cites W2169770594 @default.
• W2080335269 cites W1568370500 @default.
• W2080335269 doi "https://doi.org/10.1111/j.1742-7843.2009.00513.x" @default.
• W2080335269 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20050847" @default.
• W2080335269 hasPublicationYear "2010" @default.
• W2080335269 type Work @default.
• W2080335269 sameAs 2080335269 @default.
• W2080335269 citedByCount "66" @default.
• W2080335269 countsByYear W20803352692012 @default.
• W2080335269 countsByYear W20803352692013 @default.
• W2080335269 countsByYear W20803352692014 @default.
• W2080335269 countsByYear W20803352692015 @default.
• W2080335269 countsByYear W20803352692016 @default.
• W2080335269 countsByYear W20803352692017 @default.
• W2080335269 countsByYear W20803352692018 @default.
• W2080335269 countsByYear W20803352692019 @default.
• W2080335269 countsByYear W20803352692020 @default.
• W2080335269 countsByYear W20803352692021 @default.
• W2080335269 countsByYear W20803352692022 @default.
• W2080335269 countsByYear W20803352692023 @default.
• W2080335269 crossrefType "journal-article" @default.
• W2080335269 hasAuthorship W2080335269A5005464911 @default.
• W2080335269 hasAuthorship W2080335269A5008858755 @default.
• W2080335269 hasAuthorship W2080335269A5018442681 @default.
• W2080335269 hasAuthorship W2080335269A5028028709 @default.
• W2080335269 hasAuthorship W2080335269A5077859754 @default.
• W2080335269 hasConcept C111113717 @default.
• W2080335269 hasConcept C112705442 @default.
• W2080335269 hasConcept C185592680 @default.
• W2080335269 hasConcept C2780035454 @default.
• W2080335269 hasConcept C55493867 @default.
• W2080335269 hasConcept C64903051 @default.
• W2080335269 hasConcept C70721500 @default.
• W2080335269 hasConcept C71924100 @default.
• W2080335269 hasConcept C74187038 @default.
• W2080335269 hasConcept C86803240 @default.
• W2080335269 hasConcept C98274493 @default.
• W2080335269 hasConceptScore W2080335269C111113717 @default.
• W2080335269 hasConceptScore W2080335269C112705442 @default.
• W2080335269 hasConceptScore W2080335269C185592680 @default.
• W2080335269 hasConceptScore W2080335269C2780035454 @default.
• W2080335269 hasConceptScore W2080335269C55493867 @default.
• W2080335269 hasConceptScore W2080335269C64903051 @default.
• W2080335269 hasConceptScore W2080335269C70721500 @default.
• W2080335269 hasConceptScore W2080335269C71924100 @default.
• W2080335269 hasConceptScore W2080335269C74187038 @default.
• W2080335269 hasConceptScore W2080335269C86803240 @default.
• W2080335269 hasConceptScore W2080335269C98274493 @default.
• W2080335269 hasIssue "3" @default.
• W2080335269 hasLocation W20803352691 @default.
• W2080335269 hasLocation W20803352692 @default.
• W2080335269 hasOpenAccess W2080335269 @default.
• W2080335269 hasPrimaryLocation W20803352691 @default.
• W2080335269 hasRelatedWork W1978032370 @default.
• W2080335269 hasRelatedWork W1979757582 @default.
• W2080335269 hasRelatedWork W2071747460 @default.
• W2080335269 hasRelatedWork W2090099591 @default.
• W2080335269 hasRelatedWork W2118630726 @default.
• W2080335269 hasRelatedWork W2227061539 @default.
• W2080335269 hasRelatedWork W2332367370 @default.
• W2080335269 hasRelatedWork W2400461952 @default.
• W2080335269 hasRelatedWork W1914240745 @default.
• W2080335269 hasRelatedWork W2603979525 @default.
• W2080335269 hasVolume "106" @default.
• W2080335269 isParatext "false" @default.
• W2080335269 isRetracted "false" @default.

• next